East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
San Francisco Business Times
|
July 18, 2023
X min read
San Francisco Business Times
|
July 18, 2023
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
